Supporting a clinical strategy for a novel cancer agent


A biopharmaceutical company needed support to develop a first-in-class oncology asset.


We advanced the company’s clinical development strategy for its lead program, supported preclinical and clinical program needs, made recommendations on clinical trial design and participated in FDA document preparation and meetings.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Stay in touch